New Concepts

Best of New Concepts Award

The New Concepts Symposium sponsored by Specialised Therapeutics Australia is designed as a novel way to reach out to a wider spectrum of the group. This session provides an opportunity for delegates to present embryonic new concepts for feedback and discussion with the audience as well as comments from international guests in terms of perspective, international interest and relevance.

A good idea can be tested and a perception gained on whether to take the concept forward to a more formal review by the Upper or Lower GI Working Party. The identification of other AGITG members who may wish to assist in progressing the concept as an AGITG supported protocol is also possible.

The winner of the award will receive a $3,500 prize and a certificate. The runner up will receive a $1,500 prize and certificate both presented at the Annual Scientific Meeting Dinner.


2017 New Concepts

Concept: Biliary neoplasm, OXaliplatin, Fluorouracil Folinic acid nal‐Irinotecan ChemothErapy for late / advanced tumours (BOXOFFICE)
Presenter: Dr Andrew Dean
Reviewer: Prof John Bridgewater

Concept: A Feasibility Study using Mfolfirinox And STEreotactic Radiotherapy for Pancreatic cancer with Locally AdvaNced disease (MASTERPLAN)
Presenter: Dr Andrew Oar
Reviewer: A/Prof Thierry Alcindor

Concept: The prevalence and significance of sarcopaenia in patients with operable adenocarcinoma of the stomach or gastro‐oesophageal junction undergoing treatment with curative intent and the impact of altered body composition on chemotherapy delivery
Presenter: Dr Katherine Geddes
Reviewer: Prof John Reynolds

Concept: A Randomised, Multicentre, Open label Phase II Study of novel formulation Deflexifol in combination with Oxaliplatin (Delox) vs FOLFOX in subjects with unresectable metastatic colorectal cancer
Presenter: Prof Philip Clingan
Reviewer: Dr Ian Chau

STA logo w awardsponsor

Best of New Concepts Award - 2016

Four concepts were presented at the 2016 New Concepts Symposium.

Congratulations go to Associate Professor Eva Segelov of St Vincent's Hospital Sydney for winning the 2016 Best of New Concepts Award for her concept 'Inducing immunogenicity in rectal cancer: A Phase I/II trial of aspirin +/- PD1 inhibitor in combination with neoadjuvant chemoradiation therapy for locally advanced rectal cancer: The INTIMACCI study (Inducing Tumour IMmunogenicity with Asprin, chemoradiation and Checkpoint Inhibition).

A/Prof Segelov receives $5,000 sponsored by Specialised Therapeutics Australia and Best of New Concepts Award certificate.

STA logo w awardsponsor 1

Segelov Award resized
A/Prof Segelov is pictured receiving her award from Mr Luke Garrick from Specialised Therapeutics Australia

Best of New Concepts Award - 2015

The New Concepts Symposium featured six presentations of embryonic research concepts. Prof Rob Ramsay from the Peter MacCallum Cancer Centre won the Best New Concept for his concept "Vaccination against Adenoid cystic and Colorectal Carcinoma Using MYB cDNA – VACCUMeD clinical trial – Immune Modulatory Therapy in Colorectal and Adenoid Cystic Carcinoma". A/Prof Barbara Mullan from Curtin University and Dr Haryana Dhillon from the University of Sydney were runners up with their concept Managing bowel symptoms after colorectal cancer: an online dietary advice intervention. The AGITG thanks Specialised Therapeutics Australia for sponsoring the Best of New Concepts Symposium and Runner Up and also for sponsoring the Symposium web cast.

STA logo w awardsponsor

New concepts website 300x210

Prof Rob Ramsay, receiving his award for the New Concepts Symposium from Mr Luke Garrick and Ms Mary Rophael, Specialised Therapeutics Australia

Best of New Concepts Award - 2014

The New Concepts Symposium sponsored by Specialised Therapeutics Australia, was once again a feature in the 2014 program.  Seven concepts were presented and are featured in a web cast. Click here to view the web cast. Congratulations go to Dr Matthew Burge of Royal Brisbane Hospital for winning the Best of New Concepts Symposium Award in 2014.

Specialised Therapeutics

Award Sponsor

Dr Burge’s concept was entitled: ‘A randomised Phase 2/3 study of Infusional FU/LV with panitumumab V FU/LV/capecitabine with bevacizumab as first line therapy for never resectable, RAS and RAF wild type metastatic colorectal cancer’.

Dr David Lau from the Ludwig Institute was awarded runner up for his concept entitled: “A phase II, single arm, multi-site study utilizing ctDNA to prospectively determine the evolution of cetuximab resistance prior to radiologic progression in metastatic colorectal cancer.”